Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: Evidence to date

Francesca Cinti, Simona Moffa, Flavia Impronta, Chiara Maria Assunta Cefalo, Vinsin Alice Sun, Gianpio Sorice, Teresa Mezza, Andrea Giaccari

Risultato della ricerca: Contributo in rivistaArticolo in rivista

24 Citazioni (Scopus)


Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the latest therapeutic strategy in the treatment of type 2 diabetes mellitus (T2DM). Using an insulin-independent mechanism (glycosuria), they reduce glucose toxicity and improve insulin sensitivity and β-cell function. The promising results obtained in clinical trials show that SGLT2 significantly improves glycemic control and provides greater cardiovascular protection, combined with a reduction in body weight and blood pressure (BP). This review focuses on ertugliflozin, a new, highly selective, and reversible SGLT2 inhibitor. Clinical trials published to date show that ertugliflozin, both as a monotherapy and as an add-on to oral antidiabetic agents, is safe and effective in reducing glycosylated hemoglobin (HbA1c), body weight, and BP in T2DM patients.
Lingua originaleEnglish
pagine (da-a)2905-2919
Numero di pagine15
RivistaDrug Design, Development and Therapy
Stato di pubblicazionePubblicato - 2017


  • 3003
  • Antidiabetic drugs
  • Drug Discovery3003 Pharmaceutical Science
  • Glycemic control
  • Glycosylated hemoglobin
  • Pharmacology
  • Precision medicine
  • Sodium-glucose cotransporter 2 inhibitors
  • Type 1 diabetes mellitus
  • Type 2 diabetes mel­litus
  • Weight reduction


Entra nei temi di ricerca di 'Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: Evidence to date'. Insieme formano una fingerprint unica.

Cita questo